Search Result

Results for "

Haemophilus influenzae

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aminoacyl-tRNA Synthetase (4) Antibiotic (21) Bacterial (28) Beta-lactamase (1) DNA/RNA Synthesis (1) Drug Metabolite (5) Fungal (1) Isotope-Labeled Compounds (3) Penicillin-binding protein (PBP) (10) Reference Standards (6)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Endocrinology (4) Infection (28) Inflammation/Immunology (2) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0958

Mupirocin BRL-4910A; Pseudomonic acid	Bacterial Antibiotic Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-17593

Solithromycin 3 Publications Verification CEM-101; OP-1068	Bacterial Antibiotic	Infection
Solithromycin (CEM-101) is an orally bioavailable, effective antimicrobial agent, with IC₅₀s for inhibition of cell viability, protein synthesis, and growth rate are 7.5 ng/mL, 40 ng/mL, and 125 ng/mL for Streptococcus pneumonia, Staphylococcus aureus, and Haemophilus influenzae, respectively. Solithromycin binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis .

HY-126463

LolCDE-IN-4	Bacterial	Infection
LolCDE-IN-4 (Compound 1) is exhibits antibacterial efficacy against gram negative bacteria Escherichia coli (MIC of 0.25-32 µg/ml) and Haemophilus influenzae, through inhibition LolCDE complex and disruption of lipoproteins release from the inner membrane .

HY-W023253

Biclotymol	Bacterial Fungal	Infection Inflammation/Immunology
Biclotymol is an antimicrobial agent against gram-positive cocci. Biclotymol inhibits Streptococcus pneumoniae and Haemophilus influenzae, with MIC of 150 and 150 μM. Biclotymol exhibits anti-inflammatory and analgesic activity and ameliorates the otolaryngology infection and throat sore .

HY-161788

DNA Gyrase-IN-11	DNA/RNA Synthesis Bacterial	Infection
DNA Gyrase-IN-11 (Compound 23Be) is an inhibitor for protein synthesis (IC₅₀ is 0.74 μM) and DNA replication. DNA Gyrase-IN-11 inhibits DNA gyrase, that inhibits E. coli DNA supercoiling with IC₅₀ of 11.9 μM. DNA Gyrase-IN-11 exhibits antibacterial efficacy, that inhibits Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Staphylococcus aureus, with MICs of 0.008-0.25 μg/mL .

HY-129914

Cefcanel daloxate KY-109 free base	Bacterial	Infection
Cefcanel daloxate (KY-109 (free base)) is an orally active cephalosporin prodrug against Gram-positive bacteria and **Haemophilus influenzae**. Cefcanel daloxate is promising for research of uremia .

HY-W747311

Ritipenem	Antibiotic Bacterial Penicillin-binding protein (PBP)	Infection
Ritipenem is a penicillin antibiotic, that targets penicillin-binding protein with good affinity (IC₅₀ in levels of ng/mL), and exhibits antibacterial properties. Ritipenem exhibits antiviral activity against Haemophilus influenzae .

HY-176347S

Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2	Isotope-Labeled Compounds	Cancer
Alpha Feto Protein, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled Alpha Feto Protein.

HY-121329

Carumonam AMA-1080; Ro 17-2301	Penicillin-binding protein (PBP) Antibiotic Bacterial	Infection
Carumonam (AMA-1080; Ro 17-2301) is a sulfonated monocyclic β-Lactam Antibiotic, targeting to penicillin-binding protein (PBP). Carumonam exerts highly activity against Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae, while it weakly and even inactively inhibits Streptococcus pneumoniae and Staphylococcus aureus. Carumonam is resistant to beta-lactamase-mediated hydrolysis .

HY-159687

Nafithromycin WCK 4873	Antibiotic Bacterial	Infection
Nafithromycin (WCK 4873) is an orally available antibiotic that inhibits community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin (HY-121544)-susceptible Staphylococcus aureus. The MIC₉₀ of nafithromycin against macrolide-resistant and telithromycin (HY-A0062)-insensitive Streptococcus pneumoniae is 0.12 mg/liter .

HY-W108875

Mupirocin lithium BRL-4910A lithium; Pseudomonic acid lithium	Antibiotic Bacterial Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-135221

Cefcapene pivoxil hydrochloride	Bacterial Antibiotic	Infection
Cefcapene pivoxil hydrochloride, the pivalate ester prodrug form of Cefcapene, is an orally active third-generation cephalosporin with a wide spectrum of anti-bacterial activity. Cefcapene pivoxil hydrochloride has the potential for the palmoplantar pustulosis (PPP) research .

HY-135221R

Cefcapene pivoxil hydrochloride (Standard)	Reference Standards Bacterial Antibiotic	Infection
Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-17593R

Solithromycin (Standard) CEM-101 (Standard); OP-1068 (Standard)	Reference Standards Bacterial Antibiotic	Infection
Solithromycin (Standard) is the analytical standard of Solithromycin. This product is intended for research and analytical applications. Solithromycin (CEM-101) is an orally bioavailable, effective antimicrobial agent, with IC₅₀s for inhibition of cell viability, protein synthesis, and growth rate are 7.5 ng/mL, 40 ng/mL, and 125 ng/mL for Streptococcus pneumonia, Staphylococcus aureus, and Haemophilus influenzae, respectively. Solithromycin binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis .

HY-B0958R

Mupirocin (Standard) BRL-4910A (Standard); Pseudomonic acid (Standard)	Reference Standards Bacterial Antibiotic Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin (Standard) is the analytical standard of Mupirocin (HY-B0958). This product is intended for research and analytical applications. Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-19428

Ranbezolid RBx7644 free base	Antibiotic Bacterial	Infection Cardiovascular Disease
Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC₅₀ of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria .

HY-W108875R

Mupirocin lithium (Standard) BRL-4910A lithium (Standard); Pseudomonic acid lithium (Standard)	Antibiotic Bacterial Reference Standards Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin (lithium) (Standard) is the analytical standard of Mupirocin lithium (HY-W108875). This product is intended for research and analytical applications. Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-125579

Ro 25-0534	Bacterial	Infection
Ro 25-0534 is an antimicrobial compound against Pseudomonas. Ro 25-0534 is active against Enterobacteriaceae (MIC₉₀: 0.06-2 μg/mL), Oxacillin (HY-B0465)-susceptible staphylococci, β-hemolytic streptococci, and penicillin-susceptible pneumococci (MIC₉₀: 1-2 μg/mL), Haemophilus influenzae (MIC₉₀: 0.25-0.5 μg/mL), Moraxella catarrhalis (MIC₉₀: 0.5 μg/mL), and most nonenteric Gram-negative bacilli (MIC₉₀: 2-4 μg/mL) .

HY-A0111A

Cefetamet sodium Ro15-8074/001; Deacetoxycefotaxime sodium	Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet (Ro 15-8074) sodium is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet sodium binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet sodium has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet sodium kills and lyses Treponema pallidum. Cefetamet sodium can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-A0111B

Cefetamet hydrochloride Ro 15-8074 hydrochloride; Deacetoxycefotaxime hydrochloride	Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet (Ro 15-8074) hydrochloride is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet hydrochloride binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet hydrochloride has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet hydrochloride kills and lyses Treponema pallidum. Cefetamet hydrochloride can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-A0111

Cefetamet 1 Publications Verification Ro 15-8074; Deacetoxycefotaxime	Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-N7101

Cefpodoxime Proxetil U-76,252; CS-807	Bacterial Antibiotic Penicillin-binding protein (PBP)	Infection
Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .

HY-116815

Lalistat 1 1 Publications Verification	Beta-lactamase Bacterial	Infection Neurological Disease
Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC₅₀ of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease .

HY-A0111R

Cefetamet (Standard) Ro 15-8074 (Standard); Deacetoxycefotaxime (Standard)	Reference Standards Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet (Standard) is the analytical standard of Cefetamet (HY-A0111). This product is intended for research and analytical applications. Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-N7101R

Cefpodoxime Proxetil (Standard) U-76,252 (Standard); CS-807 (Standard)	Reference Standards Bacterial Antibiotic Penicillin-binding protein (PBP)	Infection
Cefpodoxime Proxetil (Standard) is the analytical standard of Cefpodoxime Proxetil. This product is intended for research and analytical applications. Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .

HY-W743473

Cefetamet-d3 Ro 15-8074-d₃; Deacetoxycefotaxime-d₃	Isotope-Labeled Compounds Bacterial Antibiotic Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet-d₃ (Ro 15-8074-d₃; Deacetoxycefotaxime-d₃) is the deuterium labeled Cefetamet (HY-A0111). Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-121195

Apalcillin PC-904	Bacterial	Infection
Apalcillin (PC-904) in combination with Ro 48-1220, a penam sulfone β-lactamase inhibitor, demonstrated broad-spectrum activity against gram-negative aerobic and anaerobic bacteria, excluding Klebsiella oxytoca. It exhibited potent activity against β-lactamase-producing Moraxella catarrhalis, Haemophilus influenzae, and Neisseria gonorrhoeae, with effective MICs (11 μg/mL). The combination also inhibited Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter species at low MICs (0.25 to 4 μg/mL). However, its efficacy against oxacillin-resistant staphylococci and certain gram-positive organisms was limited. Apalcillin/Ro 48-1220 showed comparable efficacy to piperacillin/tazobactam against some extended-spectrum β-lactamase-producing Escherichia coli but was less effective against SHV-type β-lactamases .

HY-B1325

Cefuroxime axetil	Bacterial Antibiotic	Infection Inflammation/Immunology
Cefuroxime axetil is an orally effective broad-spectrum β-lactam antibiotic that targets bacterial penicillin-binding proteins (PBPs, such as PBP3 and PBP1). Cefuroxime axetil inhibits cell wall synthesis, leading to bacterial lysis and death, with a minimum inhibitory concentration (MIC) of 0.12-4 mg/L for non-typeable Haemophilus influenzae (NTHi). Cefuroxime axetil is hydrolyzed by esterase to the active ingredient Cefuroxime (HY-B1256A) after oral absorption. Topical administration of Cefuroxime via bioadhesive nanoparticles (BNPs) can prolong the drug's retention time in the middle ear (≥7 days). Cefuroxime axetil can be used in the study of otitis media (especially NTHi infection). Cefuroxime axetil can achieve precise antibacterial effects through oral or topical nano-delivery systems, reducing systemic exposure and the risk of antibiotic resistance .

HY-N7101S

Cefpodoxime proxetil-d7 U-76-d₇,252-d₇; CS-807-d₇	Isotope-Labeled Compounds Bacterial Antibiotic Penicillin-binding protein (PBP)	Infection
Cefpodoxime proxetil-d₇ (U-76-d₇,252-d₇; CS-807-d₇) is the deuterium labeled Cefpodoxime Proxetil (HY-N7101). Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0958

Mupirocin BRL-4910A; Pseudomonic acid	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Disease Research Fields Other Antibiotics	Bacterial Antibiotic Aminoacyl-tRNA Synthetase
Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-B0958R

Mupirocin (Standard) BRL-4910A (Standard); Pseudomonic acid (Standard)	Structural Classification Microorganisms Antibiotics Source classification Antibacterial Disease Research Other Antibiotics	Reference Standards Bacterial Antibiotic Aminoacyl-tRNA Synthetase
Mupirocin (Standard) is the analytical standard of Mupirocin (HY-B0958). This product is intended for research and analytical applications. Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

Cat. No.	Product Name	Chemical Structure

HY-176347S

Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2
Alpha Feto Protein, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled Alpha Feto Protein.

HY-W743473

Cefetamet-d3
Cefetamet-d₃ (Ro 15-8074-d₃; Deacetoxycefotaxime-d₃) is the deuterium labeled Cefetamet (HY-A0111). Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

Cefetamet-d3

Cefetamet-d₃ (Ro 15-8074-d₃; Deacetoxycefotaxime-d₃) is the deuterium labeled Cefetamet (HY-A0111). Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-N7101S

Cefpodoxime proxetil-d7
Cefpodoxime proxetil-d₇ (U-76-d₇,252-d₇; CS-807-d₇) is the deuterium labeled Cefpodoxime Proxetil (HY-N7101). Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .

Cefpodoxime proxetil-d7

Cefpodoxime proxetil-d₇ (U-76-d₇,252-d₇; CS-807-d₇) is the deuterium labeled Cefpodoxime Proxetil (HY-N7101). Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks